A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia (ARAVA PASS)
Post Authorization Safety Study on Assessment of Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
Sponsor: Sanofi
Listed as NCT06714461, this observational or N/A phase trial focuses on Psoriatic Arthritis and Rheumatoid Arthritis and remains ongoing. Sponsored by Sanofi, it has been updated 7 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
May 4, 2026 — Present [daily]
Active Not Recruiting
-
Mar 2026 — May 2026 [monthly]
Active Not Recruiting
-
Jul 2025 — Mar 2026 [monthly]
Active Not Recruiting
Status: Not Yet Recruiting → Active Not Recruiting
-
May 2025 — Jul 2025 [monthly]
Not Yet Recruiting
-
Apr 2025 — May 2025 [monthly]
Not Yet Recruiting
▶ Show 2 earlier versions
-
Feb 2025 — Apr 2025 [monthly]
Not Yet Recruiting
-
Jan 2025 — Feb 2025 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
The main objective of this post-authorization safety study is to assess healthcare professionals' awareness, knowledge, and behavior related to receipt and reading of the Direct Healthcare Professional Communication and educational materials for ARAVA® (leflunomide) and of the additional risk minimization measures.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .